SCHEMBL11919903

SCHEMBL11919903

COc1ccc(-n2c(SCc3nc(-c4ccc(Cl)cc4)no3)nnc2-c2ccncc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 6/20 1.00
TNKS2 Q9H2K2 10/20 0.91
MAPT P10636 6/20 0.91
TNKS O95271 5/20 0.91
SMN1; SMN2 Q16637 2/20 0.91
THRB P10828 2/20 0.91
CYP3A4 P08684 2/20 0.86
CYP2C9 P11712 2/20 0.86
AXIN2 Q9Y2T1 2/20 0.86
CYP2D6 P10635 1/20 0.86
SULT2A1 Q06520 1/20 0.86
NR5A1 Q13285 1/20 0.86
LMNA P02545 3/20 0.78
HTT P42858 2/20 0.78
NPSR1 Q6W5P4 3/20 0.75
MEN1 O00255 2/20 0.69
ALDH1A1 P00352 2/20 0.69
KMT2A Q03164 2/20 0.69
USP2 O75604 2/20 0.68
MAPK1 P28482 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11919898 0.93 TNKS2 (1.00) TP53TNKS2MAPTTNKSSMN1; SMN2
SCHEMBL16010756 0.91 TNKS2 (1.00) TP53TNKS2MAPTTNKSSMN1; SMN2
SCHEMBL11919901 0.91 TP53 (1.00) TP53TNKS2MAPTTNKSSMN1; SMN2
SCHEMBL11919909 0.88 TP53 (0.84) TP53TNKS2MAPTTNKSSMN1; SMN2
SCHEMBL13048271 0.88 TP53 (0.84) TP53TNKS2MAPTTNKSSMN1; SMN2
SCHEMBL16447499 0.85 TNKS2 (1.00) TP53TNKS2MAPTTNKSSMN1; SMN2
SCHEMBL11919910 0.84 SMN1; SMN2 (0.84) TP53TNKS2MAPTTNKSSMN1; SMN2
SCHEMBL11919900 0.84 TNKS2 (0.83) TP53TNKS2MAPTTNKSSMN1; SMN2
SCHEMBL11919934 0.84 TP53 (0.72) TP53TNKS2MAPTTNKSSMN1; SMN2
SCHEMBL11919921 0.82 TNKS2 (0.76) TP53TNKS2MAPTTNKSSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed
WO-2010139966-A1 AZOLE DERIVATIVES AS WTN PATHWAY INHIBITORS OSLO UNIVERSITY HOSPITAL HF (NO) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors WNT1, AXIN2, WNT3 TP53 53/4885TNKS2 1460/4885MAPT 2763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.